Enhancer of zeste homolog 2 promotes hepatocellular cancer progression and chemoresistance by enhancing protein kinase B activation through microRNA-381-mediated SET domain bifurcated 1

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology. 2019;156(2):477–491 e471.
   PubMed Web of Science ®Google Scholar
• Carr BI. Introduction: hepatocellular carcinoma. Semin Oncol. 2012;39(4):367–368.
   PubMed Web of Science ®Google Scholar
• Hartke J, Johnson M, Ghabril M. The diagnosis and treatment of hepatocellular carcinoma. Semin Diagn Pathol. 2017;34(2):153–159.
   PubMed Web of Science ®Google Scholar
• Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379(9822):1245–1255.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Lui VW, Yeo W. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. Future Oncol. 2011;7(10):1149–1167.
   PubMed Web of Science ®Google Scholar
• Noorolyai S, Shajari N, Baghbani E, et al. The relation between PI3K/AKT signalling pathway and cancer. Gene. 2019;698:120–128.
   PubMed Web of Science ®Google Scholar
• Liu R, Chen Y, Liu G, et al. PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers. Cell Death Dis. 2020;11(9):797.
   PubMed Web of Science ®Google Scholar
• Zhang XL, Jia Q, Lv L, et al. Tumorspheres derived from HCC cells are enriched with cancer stem cell-like cells and present high chemoresistance dependent on the AKT pathway. Anticancer Agents Med Chem. 2015;15(6):755–763.
   PubMed Web of Science ®Google Scholar
• Guo J, Dai X, Laurent B, et al. AKT methylation by SETDB1 promotes AKT kinase activity and oncogenic functions. Nat Cell Biol. 2019;21(2):226–237.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Huang J, Li Q, et al. Histone methyltransferase SETDB1 promotes cells proliferation and migration by interacting withTiam1 in hepatocellular carcinoma. BMC Cancer. 2018;18(1):539.
   PubMed Web of Science ®Google Scholar
• Wang W, Wang J, Zhang X, et al. Serum circSETDB1 is a promising biomarker for predicting response to platinum-taxane-combined chemotherapy and relapse in high-grade serous ovarian cancer. Onco Targets Ther. 2019;12:7451–7457.
   PubMed Web of Science ®Google Scholar
• Liu B, Ye B, Yang L, et al. Long noncoding RNA lncKdm2b is required for ILC3 maintenance by initiation of Zfp292 expression. Nat Immunol. 2017;18(5):499–508.
   PubMed Web of Science ®Google Scholar
• Gao J, Ma S, Yang F, et al. miR193b exhibits mutual interaction with MYC, and suppresses growth and metastasis of osteosarcoma. Oncol Rep. 2020;44(1):139–155.
   PubMed Web of Science ®Google Scholar
• Liu Y, Cao Y, Cai W, et al. Aberrant expression of two miRNAs promotes proliferation, hepatitis B virus amplification, migration and invasion of hepatocellular carcinoma cells: evidence from bioinformatic analysis and experimental validation. PeerJ. 2020;8:e9100.
   PubMed Web of Science ®Google Scholar
• Mens MMJ, Ghanbari M. Cell cycle regulation of stem cells by MicroRNAs. Stem Cell Rev Rep. 2018;14(3):309–322.
   PubMed Web of Science ®Google Scholar
• Wu M, Fan B, Guo Q, et al. Knockdown of SETDB1 inhibits breast cancer progression by miR-381-3p-related regulation. Biol Res. 2018;51(1):39.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Du DH, Wang J, et al. Identification of catalytic and non-catalytic activity inhibitors against PRC2-EZH2 complex through multiple high-throughput screening campaigns. Chem Biol Drug Des. 2020;96(4):1024–1051.
   PubMed Web of Science ®Google Scholar
• Dou D, Ge X, Wang X, et al. EZH2 contributes to cisplatin resistance in breast cancer by epigenetically suppressing miR-381 expression. Onco Targets Ther. 2019;12:9627–9637.
   PubMed Web of Science ®Google Scholar
• Wang XJ, Li FF, Zhang YJ, et al. TRIB3 promotes hepatocellular carcinoma growth and predicts poor prognosis. Cancer Biomark. 2020;29(3):307–315.
   PubMed Web of Science ®Google Scholar
• Chen L, Long Y, Han Z, et al. MicroRNA-101 inhibits cell migration and invasion in bladder cancer via targeting FZD4. Exp Ther Med. 2019;17(2):1476–1485.
   PubMed Web of Science ®Google Scholar
• Wang G, Long J, Gao Y, et al. SETDB1-mediated methylation of Akt promotes its K63-linked ubiquitination and activation leading to tumorigenesis. Nat Cell Biol. 2019;21(2):214–225.
   PubMed Web of Science ®Google Scholar
• Chen Y, Peng C, Chen J, et al. WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1. Mol Cancer. 2019;18(1):127.
   PubMed Web of Science ®Google Scholar
• Song J, Xie C, Jiang L, et al. Transcription factor AP-4 promotes tumorigenic capability and activates the Wnt/beta-catenin pathway in hepatocellular carcinoma. Theranostics. 2018;8(13):3571–3583.
   PubMed Web of Science ®Google Scholar
• Yang YF, Zhang MF, Tian QH, et al. SPAG5 interacts with CEP55 and exerts oncogenic activities via PI3K/AKT pathway in hepatocellular carcinoma. Mol Cancer. 2018;17(1):117.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Zhao S, Pang X, et al. MicroRNA-381 suppresses cell growth and invasion by targeting the liver receptor homolog-1 in hepatocellular carcinoma. Oncol Rep. 2016;35(3):1831–1840.
   PubMed Web of Science ®Google Scholar
• Xiao G, Jin LL, Liu CQ, et al. EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma. J Immunother Cancer. 2019;7(1):300.
   PubMed Web of Science ®Google Scholar
• Wong CM, Ng IO. Molecular pathogenesis of hepatocellular carcinoma. Liver Int. 2008;28(2):160–174.
   PubMed Web of Science ®Google Scholar
• Shao Y, Song X, Jiang W, et al. MicroRNA-621 acts as a tumor radiosensitizer by directly targeting SETDB1 in hepatocellular carcinoma. Mol Ther. 2019;27(2):355–364.
   PubMed Web of Science ®Google Scholar
• Martini M, De Santis MC, Braccini L, et al. PI3K/AKT signaling pathway and cancer: an updated review. Ann Med. 2014;46(6):372–383.
   PubMed Web of Science ®Google Scholar
• Song M, Bode AM, Dong Z, et al. AKT as a therapeutic target for cancer. Cancer Res. 2019;79(6):1019–1031.
   PubMed Web of Science ®Google Scholar
• Pirim D. Integrative analyses of molecular pathways and key candidate biomarkers associated with colorectal cancer. Cancer Biomark. 2020;27(4):555–568.
   PubMed Web of Science ®Google Scholar
• Wang S, Cai L, Zhang F, et al. Inhibition of EZH2 attenuates sorafenib resistance by targeting NOTCH1 activation-dependent liver cancer stem cells via NOTCH1-related MicroRNAs in hepatocellular carcinoma. Transl Oncol. 2020;13(3):100741.
   PubMed Web of Science ®Google Scholar
• Li T, Li Z, Wan H, et al. Recurrence-associated long non-coding RNA LNAPPCC facilitates colon cancer progression via forming a positive feedback loop with PCDH7. Mol Ther Nucleic Acids. 2020;20:545–557.
   PubMedGoogle Scholar
• Lee S, Woo DC, Kang J, et al. The role of the histone methyltransferase EZH2 in liver inflammation and fibrosis in STAM NASH mice. Biology (Basel). 2020;9(5):93.
   PubMed Web of Science ®Google Scholar
• Nakayama H, Kawachi K, Suganuma N, et al. EZH2 and MMSET were identified as potentially useful therapeutic targets in metaplastic breast carcinoma. Anticancer Res. 2020;40(4):2133–2139.
   PubMed Web of Science ®Google Scholar
• Xu X, Gu J, Ding X, et al. LINC00978 promotes the progression of hepatocellular carcinoma by regulating EZH2-mediated silencing of p21 and E-cadherin expression. Cell Death Dis. 2019;10(10):752.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Tang B, Song J, et al. Lnc-PDZD7 contributes to stemness properties and chemosensitivity in hepatocellular carcinoma through EZH2-mediated ATOH8 transcriptional repression. J Exp Clin Cancer Res. 2019;38(1):92.
   PubMed Web of Science ®Google Scholar